The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Precision Medicine for Lupus Continues to Progress

Precision Medicine for Lupus Continues to Progress

June 21, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
HelloRF Zcool / shutterstock.com

HelloRF Zcool / shutterstock.com

CHICAGO—The promise of precision medicine—the tailoring of treatment to a given patient based on genetics and other factors—has probably been best illustrated in oncology, with therapies targeted specifically to markers expressed on tumors. But rheumatology is in the thick of precision medicine as well, said Judith James, MD, PhD, chair of the arthritis and clinical immunology program at the Oklahoma Medical Research Foundation in Oklahoma City.

You Might Also Like
  • The ACR Pre-Meeting Research Conferences to Explore Immunity, Precision Medicine in Rheumatic Diseases
  • Advances in Precision Immunology Require Precision Controls to Further Research
  • Experts Discuss the Latest Precision Medicine Research
Explore This Issue
June 2018
Also By This Author
  • Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App

Compared with other specialties, rheumatology has historically had the highest number of biomarker tests approved by the U.S. Food & Drug Administration, mainly because so many autoantibody tests are used. At the ACR State-of-the-Art Clinical Symposium in April, Dr. James showed how new lupus research is attempting to fuse genetics and other data into practical information that can be used patient-by-patient in the clinic.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lupus Subsets

This will benefit patients across the rheumatology sphere, but especially in systemic lupus erythematosus (SLE), which manifests in many ways. In the same waiting room, Dr. James said, one patient could mainly suffer from fatigue that makes daily errands difficult, while another’s kidneys have shut down, forcing them onto dialysis.

“The big challenge in lupus is that we have a lot of heterogeneity,” she said. “We hope we can start taking lupus patients and finding different subsets.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In one of the largest genetic lupus studies published last year, 50,000 unique parts of the genome were interrogated in 27,000 people, including patients and controls.1 Genetic associations, such as tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), signal transducer and activator of transcription 4 (STAT4) and tyrosine kinase 2 (TYK2), were identified. And Dr. James said researchers are also beginning to see novel associations in African-Americans and Hispanics that haven’t been seen before.

“We have identified genetic associations that may account for more than 50% of the heritable risk of lupus among patients of European-American descent based upon these studies and the other published data,” she said.

But genetics tell only part of the story, she said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Genetics are usually what we think of with precision medicine,” she said. “I think that what we’re learning from the genetics in our diseases is that genetics alone are probably not going to be all we need to be able to inform us about how to treat our patients.”

In studies based on the Dallas Pediatric SLE Cohort, clinical and blood transcriptional profiles were collected from 158 pediatric patients and 48 healthy controls over time for up to four years, with SLE Disease Activity Index components and medication use recorded for every visit.2 (The Dallas group has modules available that allow clinicians from elsewhere to enter data from their own patients to see their risk of flare.)

Dr. James

Pages: 1 2 | Single Page

Filed Under: Meeting Reports, SLE (Lupus) Tagged With: 2018 State of the Art Clinical Symposium, Lupus, Precision MedicineIssue: June 2018

You Might Also Like:
  • The ACR Pre-Meeting Research Conferences to Explore Immunity, Precision Medicine in Rheumatic Diseases
  • Advances in Precision Immunology Require Precision Controls to Further Research
  • Experts Discuss the Latest Precision Medicine Research
  • Progress Continues in Systemic Sclerosis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)